Near-infrared light-controlled nanonucleic acid PROTAC molecules and preparation methods and applications thereof

By designing near-infrared photocontrolled nanonucleic acid PROTAC molecules, using the binding method of nanoparticles and oligonucleotide DNA, the problem of drug delivery difficulties and phototoxicity of photoresponsive PROTAC in the prior art is solved, and efficient and low-toxic transcription is achieved Targeted degradation of factors enhances the therapeutic effect.

CN116712558BActive Publication Date: 2024-11-01HUNAN FIRST NORMAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310658992.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-05
Publication Date
2024-11-01
Estimated Expiration
2043-06-05

AI Technical Summary

Technical Problem

In the prior art, oligonucleotide-based PROTACs have difficulty delivering drugs due to a large amount of negative charge carried by DNA components, poor pharmacokinetics, low potency, and may produce off-target toxicity, and photo-tissue of photoresponsive PROTACs. Poor penetration and potential phototoxicity are problematic, which limits its clinical application.

Method used

Design a near-infrared photocontrolled nanonucleic acid PROTAC molecule, which binds biotinylated APC to streptavidin-coated SA-UCNP, using psDNA10 with photocleavable groups and azide-modified E3 enzyme Linking ligands, through azide-alkyne cycloaddition reaction and biotin-streptavidin covalent action, a nanonucleic acid PROTAC system is constructed to achieve near-infrared light response and targeted delivery.

Benefits of technology

It improves the spatiotemporal resolution and targeted delivery of PROTAC, reduces phototoxicity, enhances tissue penetration, and achieves selective degradation of transcription factors, reduces potential toxicity to normal cells and improves therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116712558B_ABST
    Figure CN116712558B_ABST
Patent Text Reader

Abstract

The present invention discloses a near-infrared light-controlled nanonucleic acid PROTAC molecule and a preparation method and application thereof. The near-infrared light-controlled nanonucleic acid PROTAC molecule includes a biotinylated APC and a streptavidin-coated modified SA-UCNP, wherein the biotinylated APC is bound to the streptavidin-coated modified SA-UCNP through a biotin-streptavidin interaction; the biotinylated APC is formed by a masking aptamer chain modified with biotin and a psDNA10 with a photocleavable group through complementary pairing. The PROTACS molecule of the present invention has better optical window, tissue penetration, targeted delivery and low phototoxicity, can achieve near-infrared light response, targeted delivery and selective degradation of transcription factors, and can be used to prepare drugs for degrading tumor transcription factors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the biological field and relates to a near-infrared light-controlled nano nucleic acid PROTAC molecule and a preparation method and application thereof. Background Art

[0002] Many diseases are caused by abnormal expression, folding and aggregation of proteins, and most of these proteins are regarded as important therapeutic targets for drug development. The typical treatment method is to develop small molecules that can selectively inhibit the functions of these proteins. Although a variety of auxiliary technologies have been developed for drug development, there are still many practical problems to be solved, such as how to achieve efficient drug delivery and targeted drug development for undruggable targets. Traditional small molecule drugs (SMDs), as low molecular weight, high cell permeability and high selectivity compounds, are a good clinical oral drug inhibitor, but due to their drug resistance and low efficiency, they are subject to many restrictions in cancer treatment. Only about 20% of cellular proteins in the human body have potential targeting and can be developed into SMDs, and most important tumor target types, such as transcription factor (TF) proteins, are undruggable. Therefore, it is very meaningful to develop a controllable drug delivery system that can highly specifically identify and target "undruggable" targets.

[0003] PROTAC drugs are bifunctional molecules connected by chemical linkers. One end of the PROTAC drug binds to the target protein (POI) and the other end recruits the E3 ubiquitin ligase. When the PROTAC molecule is coupled to the POI, the E3 can be recruited to the POI to mark the target protein with ubiquitin, and then the POI is degraded by the ubiquitin-proteasome pathway system, and the PROTAC molecule is recycled and reused in the next cycle. Conventional small molecule drug design strategies require that the drug can not only bind specifically to the substrate, but also exert biologically active functions on the POI, which makes most tumor marker molecules that do not have ligands seem to be "undruggable". The PROTAC system can design a simple ternary structure of POI ligand, linker structure and E3 ligase ligand, without adhering to the active site, but only through the E3 ligase ligand to trigger the ubiquitination cascade reaction. In theory, it can be targeted to eliminate any "undruggable" targets such as overexpressed proteins and mutant proteins. So far, many research groups have used this technology to develop new methods for tumor treatment, opening up a new drug design strategy.

[0004] Among them, small molecule-based PROTACs have shown great clinical promise, but how to select a suitable ligand to target TF is still a difficult problem. Oligonucleotide DNA, as the natural binding ligand of TF, is stable in nature, can penetrate tissues, and has low immunogenicity and toxicity. Therefore, nucleic acid-based PROTACs have multiple advantages. It can not only target and bind to undruggable sites, but also flexibly and conveniently replace the DNA part to adapt to targeting other transcription factors. It is a regulatory method with universality, flexibility and high targeting.

[0005] The research group of Professor Jin Jian at the Icahn School of Medicine at Mount Sinai and the research group of Professor Wei Wenyi at Harvard Medical School have successfully developed a universal targeted degradation strategy (TF-PROTACs) for transcription factors using the above transcription factor binding domains. Figure 1 , they synthesized a series of BCN-modified VHL E3 ligase ligands (VHLL-X-BCN) of different lengths, as well as azide-modified short-chain DNA (N3-ODN) that specifically binds to the target protein transcription factor. Then, using the "click" reaction (SPAAC reaction) of azide and cyclooctyne, the two were combined to obtain TF-PROTAC molecules. After entering tumor cells, these molecules can recruit corresponding transcription factors and mediate their degradation. As a conceptual research result, they selected two transcription factors with relatively clear binding domain base sequences, NF-κB and E2F, as target proteins for study.

[0006] This study broke through the bottleneck of small molecule inhibitors of transcription factors and achieved the selective degradation of targets that are traditionally considered "undruggable", which is of great significance for targeted cancer therapy. However, oligonucleotide-based PROTACs are more difficult to deliver drugs due to the large amount of negative charges carried by their DNA components, and have poor pharmacokinetics and low efficacy. At the same time, through systematic research on PROTAC technology, people have found that this technology usually degrades proteins in cells or tissues in a non-selective manner, which may cause off-target toxicity. In order to solve this problem, the researchers proposed Pro-PROTAC: conditionally regulating the targeted degradation activity of PROTAC molecules through different response modes, thereby improving the spatiotemporal resolution of PROTAC and improving the potential toxicity of PROTAC to normal cells.

[0007] The research group of Pan Zhengying from Peking University introduced the photocontrol group DMNB into the PROTAC molecule (dBET1) that degrades the BRD4 protein, and synthesized the photocaged PROTAC (pc-PROTAC) for the first time. PC-PROTAC uses ultraviolet light activation to improve the spatiotemporal resolution of PROTAC. Specifically, it is an inert molecule before illumination, but after illumination, it can effectively degrade the target protein in cells and zebrafish (see the attached manual). Figure 2 ). At the same time, other excellent research groups also explored the synthetic design of different photocage protecting groups on PROTAC molecules, expanding the application of photocage strategy in PROTAC molecular design.

[0008] Although photoresponsive Pro-PROTAC molecules improve PROTAC off-target toxicity through light-controlled conditions, there is still a long way to go before this type of molecule can be truly applied in clinical treatment due to problems such as poor tissue penetration of light and potential phototoxicity, as well as limited types of proteins targeted by small molecules. Summary of the invention

[0009] The technical problem to be solved by the present invention is to overcome the technical problems existing in the prior art and provide a near-infrared light-controlled nanonucleic acid PROTAC molecule and a preparation method and application thereof. Compared with other PROTACS molecules, this nanonucleic acid PROTACS molecule has better optical window, tissue penetrability, targeted delivery and low phototoxicity, and can achieve near-infrared light response, targeted delivery and selective degradation of transcription factors.

[0010] In order to solve the above technical problems, a near-infrared light-controlled nanonucleic acid PROTAC molecule is provided, comprising a biotinylated APC and a SA-UCNP modified with a streptavidin coating, wherein the biotinylated APC is bound to the SA-UCNP modified with a streptavidin coating through a biotin-streptavidin interaction; the biotinylated APC is formed by a masking aptamer chain modified with biotin and a psDNA10 with a photocleavable group through complementary pairing;

[0011] The psDNA10 with a photocleavable group comprises psDNA10, a PC group and a fragment having both an AS1411 aptamer and being complementary to a Masking aptamer; the DNA sequence of the psDNA10 is shown in SED ID NO.1;

[0012] The DNA sequence of the masking aptamer chain is shown in SED ID NO.2.

[0013] The above-mentioned near-infrared light-controlled nanonucleic acid PROTAC molecule, further, the DNA sequence of the psDNA10 with a photocleavable group is shown in SED ID NO.3.

[0014] The above-mentioned near-infrared light-controlled nanonucleic acid PROTAC molecule, further, the DNA sequence of the maskingaptamer chain modified with biotin is shown in SED ID NO.4.

[0015] In the above-mentioned near-infrared light-controlled nanonucleic acid PROTAC molecule, further, one end of the psDNA10 with a photocleavable group is modified with an azide group; the E3 enzyme-linked ligand is modified on the psDNA10 with a photocleavable group through an azide-alkyne cycloaddition reaction.

[0016] Based on a general technical concept, the present invention also provides a method for preparing the near-infrared light-controlled nanonucleic acid PROTAC molecule, comprising the following steps:

[0017] S1, modifying the alkynyl group on the E3 enzyme-linked ligand to obtain an alkynylated E3 enzyme-linked ligand;

[0018] S2, subjecting the alkynylated E3 enzyme-linked ligand and the psDNA10 with a photocleavable group to an azide-alkyne cycloaddition reaction under the action of a copper catalyst to obtain the psDNA10 with an E3 enzyme-linked ligand and a photocleavable group;

[0019] S3, annealing and hybridizing the masking aptamer chain modified with biotin and the psDNA10 with the E3 enzyme-linked ligand and the photocleavable group to form a biotinylated APC;

[0020] S4. The biotinylated APC is bound to the SA-UCNP modified with the streptavidin coating through the biotin-streptavidin interaction to obtain a near-infrared light-controlled nanonucleic acid PROTAC molecule.

[0021] In the above preparation method, further, the E3 enzyme-linked ligand in S1 is thalidomide.

[0022] The above-mentioned preparation method, further, the preparation method of alkynylated thalidomide comprises the following steps:

[0023] S1-1, 2-(2-(propan-2-yn-1-yloxy)ethoxy)-1-amine, 2-(2,6-dioxy-3-yl)-4-fluoroisoindole-1,3-dione and N-ethyl-N-isopropyl-2-amine are mixed and stirred in dry N,N-dimethylformamide to obtain a mixture;

[0024] S1-2, extracting the mixture with ethyl acetate to obtain an extract;

[0025] S1-3. The extract is washed with an organic phase and brine successively, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain alkynyl thalidomide.

[0026] In the above preparation method, further, the copper catalyst in S2 includes THPTA, sodium ascorbate and CuSO4.

[0027] Based on a general technical concept, the present invention also provides an application of the near-infrared light-controlled nanonucleic acid PROTAC molecule in degrading tumor transcription factors.

[0028] In the above application, further, the concentration of the near-infrared light-controlled nanonucleic acid PROTAC molecule is 10 μg / mL to 40 μg / mL.

[0029] Compared with the prior art, the advantages of the present invention are:

[0030] (1) The present invention provides a near-infrared light-controlled nanonucleic acid PROTAC molecule. Unlike most small molecule inhibitors that mainly block the catalytic activity of the target enzyme, PROTACs are designed to degrade the target protein. This feature provides advantages as well as potential disadvantages. When administered systemically, it may cause uncontrolled degradation of the target protein in normal cells and produce non-specific toxicity. The light-controlled switch PROTACs add a controllable switch to PROTAC, making it inactive in the dark and activated by visible light of a specific wavelength to degrade the target protein. Therefore, the light-controlled switch PROTACs can be activated in cancer cells or tissues, precisely controlling the degradation of targeted proteins in time and space, and eliminating potential non-specific toxicity. At the same time, in order to reduce the problems of poor tissue penetration and potential phototoxicity of ultraviolet light, upconversion nanoparticles are introduced to convert ultraviolet light into cell-friendly near-infrared light and enhance its tissue penetration.

[0031] (2) The present invention provides a near-infrared light-controlled nanonucleic acid PROTAC molecule based on the characteristics of oligonucleotide DNA: such as being able to serve as a natural binding ligand for TF, being stable in nature, being able to penetrate tissues, and having low immunogenicity and toxicity. It can not only target and bind to undruggable sites, but also flexibly and conveniently replace the DNA part to target other transcription factors. By utilizing the characteristics of oligonucleotides, a means of photo-regulated transcription factor degradation with versatility, flexibility and high targeting is designed. In order to solve the problem that oligonucleotide-based PROTACs are more difficult to deliver drugs due to the large amount of negative charge carried by their DNA components, and have poor pharmacokinetics and low efficacy, nanoparticles are introduced to enhance their delivery and drug treatment effects.

[0032] (3) The present invention provides a near-infrared light-controlled nanonucleic acid PROTAC molecule, which uses a natural ligand such as oligonucleotide DNA to modify the photocleavable group to the DNA that can bind to the transcription factor. In order to construct the E3 recruitment end in the PROTAC molecule, an E3 enzyme-linked ligand containing an alkyne group at one end is prepared by chemical synthesis technology, and the azide-alkyne click chemistry reaction can be used to achieve binding with an azide-modified light-responsive oligonucleic acid molecule. The photocleavable group and the nucleic acid chain modified by the E3 ligase are covalently linked to UCNP through biotin-streptavidin to form a nanonucleic acid PROTAC system, which enters the cell through endocytosis. Under near-infrared light excitation, a nucleic acid chain that can recruit E3 ubiquitinase at one end and pSMAD3 at the other end is released from the UCNP. The released nucleic acid chain binds to the pSMAD3 transcription factor and the E3 ubiquitinase to form a ternary complex. Targeted degradation of pSMAD3 is achieved under the action of the proteasome. Compared with previous studies, the present invention newly introduces a near-infrared light-responsive nanodelivery system, which can achieve targeted delivery and near-infrared light-responsive release of nucleic acid PROTACS molecules.

[0033] (4) The present invention provides a near-infrared light-controlled nanonucleic acid PROTAC molecule. Compared with other PROTACS molecules, this near-infrared light-controlled nanonucleic acid PROTACS molecule has better optical window, tissue penetration, targeted delivery and low phototoxicity, and can achieve near-infrared light response, targeted delivery and selective degradation of transcription factors.

[0034] (5) The present invention provides a method for preparing near-infrared light-controlled nanonucleic acid PROTAC molecules, which combines nanoparticles with nucleic acids for the first time to prepare nanonucleic acid PROTAC molecules. For the first time, the advantages of nucleic acid palindromic sequences are utilized to rationally design nucleic acid sequences so that one end can target transcription factors and the other end can target E3 ubiquitinase, thereby improving the ability to degrade transcription factors.

[0035] In addition to the above-described purposes, features and advantages, the present invention has other purposes, features and advantages. The present invention will be further described in detail below with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] The drawings constituting a part of this application are used to provide a further understanding of the present invention. The illustrative embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0037] Figure 1 Schematic diagram of the TF-PROTAC strategy for specifically degrading transcription factors using short-chain DNA in the background technology.

[0038] Figure 2It is a photocage protecting group commonly used in pc-PROTAC and photocaged PROTAC in the background technology.

[0039] Figure 3 This is a schematic diagram of the preparation principle of the near-infrared light-controlled nanonucleic acid PROTAC molecule in Example 1 of the present invention.

[0040] Figure 4 The synthetic route of the E3-linked small molecule alkynylated CRBN ligand thalidomide in Example 1 of the present invention.

[0041] Figure 5 This is the hydrogen nuclear magnetic resonance spectrum of the alkynylated CRBN ligand thalidomide in Example 1 of the present invention.

[0042] Figure 6 The azide-modified nucleic acid psDNA is linked to the alkynylated thalidomide psDTC by click chemistry in Experiment 1 of the present invention. In the figure, (a) the principle diagram of thalidomide and psDNA being linked by click chemistry; (b) gel electrophoresis of psDNA and psDTC; (c) superimposed mass spectra of psDNA (gray) and psDTC.

[0043] Figure 7 The figure shows the assembly diagram of the photo-controllable E3 ligase nucleic acid (APC) in Experiment 1 of the present invention. In the figure, (a) APC in vitro assembly gel electrophoresis diagram: masking aptamer (Ⅰ), psDNA10 (Ⅱ), APC (Ⅲ), APC ultraviolet irradiation product (Ⅳ); (b) the effect of different ultraviolet irradiation time (0, 0.5, 1, 5, 10, 20, 30min) on the dissociation kinetics of APC.

[0044] Figure 8 Characterization analysis of the upconversion nanoparticles UCNP and UCNP@APC in Experiment 2 of the present invention. In the figure, (a) transmission electron microscopy image of UCNP; (b) emission spectra of UCNP and UCNP@APC under near-infrared light irradiation; (c) particle size distribution of UCNP and UCNP@APC; (d) potential diagram of UCNP and UCNP@APC.

[0045] Fig. 9 This is the result of the inhibition of TGF-β-stimulated MCF-7 cell migration by PASTE in Example 2 of the present invention.

[0046] Fig.10 Figure 3 of the in vitro NIR-responsive cleavage investigation of UCNP@APC in Experiment 3 of the present invention.

[0047] Fig.11The results of evaluating the degradation effect of p-smad3 using the controlled variable method in Experiment 4 of the present invention; in the figure, (a) the protein degradation results of psDTC with three different linker lengths delivered into the body (psDNA0, psDNA10, psDNA30); (b) the feasibility study results of light-responsive APC as a PROTAC molecule for degradation; (c) the feasibility study results of NIR-responsive UCNP@APC as a PROTAC molecule for p-Smad3 protein degradation.

[0048] Fig.12 This is the near-infrared light time dependence of UCNP@APC in Experiment 5 of the present invention to degrade p-Smad3.

[0049] Fig.13 This is the concentration-dependent result of UCNP@APC degradation of p-Smad3 in Experiment 6 of the present invention.

[0050] Fig.14 This is the result of exploring the p-Smad3 degradation mechanism mediated by NIR-responsive UCNP@APC in Experiment 7 of the present invention.

[0051] Fig.15 This is a graph analyzing the cytotoxicity of UCNP@APC and near-infrared irradiation time on MCF-7 cells in Experiment 8 of the present invention. DETAILED DESCRIPTION

[0052] The present invention will be further described below in conjunction with the accompanying drawings and specific preferred embodiments, but the protection scope of the present invention is not limited thereby. The present invention will be described in detail below with reference to the accompanying drawings and in conjunction with embodiments.

[0053] The materials and instruments used in the following examples are all commercially available. Table 1 lists the main reagents and materials used in the following examples, Table 2 lists the main instruments and equipment used in the following examples, and Table 3 lists the DNA sequences involved in the following examples.

[0054] Table 1: Main reagents and materials required for this example

[0055]

[0056]

[0057] Table 2: Main instruments and equipment required for this example

[0058]

[0059] Table 3: DNA detailed sequence information

[0060]

[0061]

[0062] Example 1

[0063] A near-infrared light-controlled nanonucleic acid PROTAC molecule, including Photocleavable psDNA10, Biotinylated masking aptamer and streptavidin-coated modified SA-UCNP.

[0064] The DNA sequence of PsDNA10 is: (The single underlined part in the sequence will self-bind into double-stranded DNA in the cellular environment, and the bold part represents the main nucleic acid sequence bound by the psmad3 protein).

[0065] The psDNA10 with a photocleavable group is Photocleavable psDNA10, which includes psDNA10, a PC group, and a fragment having both an AS1411 aptamer and being complementary to a Masking aptamer, and its DNA sequence is:

[0066]

[0067] In the sequence, the double underlined part is the sequence that can complement the masking aptamer, and the bold part represents the main nucleic acid sequence that the psmad3 protein binds.

[0068] The masking aptamer chain modified with biotin is called Biotinylated masking aptamer, and its DNA sequence is:

[0069] The double-underlined part is the fragment that can complementarily pair with Photocleavable psDNA10.

[0070] The biotinylated masking aptamer chain was annealed and hybridized with Photocleavable psDNA10 at 95°C for 5 minutes to form a biotinylated APC. The biotinylated APC was bound to the streptavidin-coated SA-UCNP through the biotin-streptavidin interaction at 37°C overnight to obtain a near-infrared light-controlled nanonucleic acid PROTAC molecule.

[0071] The construction principle of the above biotinylated APC is to use the DNA bound by psDNA10 as a palindromic sequence, which will self-bind into double-stranded DNA in the cell environment; first, the PC group is modified in the sequence that can bind to pSMAD10, and a masking aptamer that is partially complementary to it and has an AS1411 aptamer is designed (Photocleavable psDNA10 is a sequence modified with a PC group and carrying psDNA10 and a sequence that can complement the masking aptamer). After the complementary base pairing of PhotocleavablepsDNA10 and Biotinylated masking aptamer, they can break under ultraviolet light to form a new type of psDTC, and then self-assemble and dimerize into active PASTE in the intracellular environment. The other end of the biotinylated APC is modified with an azide group to facilitate the modification of the E3 enzyme-linked ligand.

[0072] Figure 3 This is a schematic diagram of the preparation of near-infrared light-controlled nanonucleic acid PROTAC molecules. In the figure, Biotinylated APC is biotinylated APC. It can be seen from the figure that the biotinylated APC and the SA-UCNP modified with streptavidin coating were combined and assembled to successfully construct an active UCNP@APC tool, which released active PASTE under the stimulation of near-infrared light to mediate the initiation of PROTAC reaction in cells.

[0073] The specific construction method is:

[0074] (1) Preparation of E3 enzyme-linked ligand thalidomide:

[0075] 1.1. 2-(2-(propan-2-yn-1-yloxy)ethoxy)-1-amine (143 mg, 1 mmol), 2-(2,6-dioxy-3-yl)-4-fluoroisoindole-1,3-dione (276 mg, 1 mmol) and N-ethyl-N-isopropyl-2-amine (129 mg, 1 mmol) were mixed in dry N,N-dimethylformamide (2 mL) and stirred for 12 hours to obtain a mixture.

[0076] 1.2. Cool the above mixture to room temperature, pour it into 20 mL of water, and extract with 35 mL of ethyl acetate to obtain an extract.

[0077] 1.3. The extract was washed with 30 mL of organic phase and 30 mL of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude residue. The crude residue was purified by preparative thin layer chromatography to obtain 2-(2,6-dioxy-3-yl)-4-((2-(2-(propan-2-n-1-yloxy)ethoxy)ethyl)amino)isoindole-1,3-dione (155 mg, yield 39%) as a yellow solid.

[0078] Figure 4 Figure 2 is a diagram of the synthesis method of the alkynylated CRBN ligand thalidomide.

[0079] Figure 5 The results of hydrogen nuclear magnetic resonance spectrum are as follows: 1H NMR (400MHz, CDCl3) δ: 8.27 (s, 1H), 7.51 (t, J = 7.8Hz, 1H), 7.12 (d, J = 7.1Hz, 1H), 6.95 (d, J = 8.5Hz, 1H), 5.32 (s, 1H), 4.94 (dd, J = 11.7, 5.0Hz, 1H), 4.23 (s, 2H), 3.77-3.68 (m, 6H), 3.50 (t, J = 5.0Hz, 2H), 2.92-2.71 (m, 3H), 2.45 (s, 1H), 2.17-2.08 (m, 1H); 13C NMR (100MHz, CDCl3) δ: 171.08, 169.28, 168.35, 167.61, 146.87, 136.03, 132.51, 116.81, 111.68, 110.33, 79.63, 74.59, 70.48, 69.62, 69.18, 58.48, 48.88, 42.43, 31.42, 22.78. The NMR results showed that the alkynylated CRBN ligand thalidomide was successfully prepared.

[0080] (2) Coupling of small molecules with psDNA using copper-catalyzed azide-alkyne cycloaddition reaction:

[0081] 2.1. First, in the presence of Cu(I) stabilizing ligand THPTA (1 mM), 0.2 mM CuSO4 was reduced with 2 mM sodium ascorbate to prepare a catalyst mixture.

[0082] 2.2. Add 1 mM CRBN ligand thalidomide and psDNA (2OD) to the above solution, adjust the final reaction volume to 30 μL, and incubate at 37°C for 2 h.

[0083] 2.3. Add 30 μL 5M sodium acetate and 300 μL ethanol to the reaction mixture in step 2.2 and store at -20°C overnight. Centrifuge the sample at 15,000 rpm for 15 min and wash with 500 μL pre-frozen 75% ethanol in autoclaved water. Centrifuge the sample again at 15,000 rpm for 15 min to obtain Photocleavable psDNA10 modified with CRBN ligand thalidomide, and finally dissolve the product in RNase-free water.

[0084] (3) Biotinylated APC was assembled on SA-UCNP modified with streptavidin coating. The specific process was as follows: the biotinylated masking aptamer chain was annealed and hybridized with PhotocleavablepsDNA10 modified with CRBN ligand thalidomide at 95°C for 5 minutes to form biotinylated APC. The biotinylated APC was bound to the streptavidin-coated SA-UCNP through biotin-streptavidin interaction at 37°C overnight to obtain a near-infrared light-controlled nanonucleic acid PROTAC molecule.

[0085] The present invention utilizes the natural ligand of oligonucleotide DNA to modify the photocleavable group to the DNA that can bind to the transcription factor. In order to construct the E3 recruitment end in the PROTAC molecule, an E3 enzyme-linked ligand containing an alkyne group at one end is prepared by chemical synthesis technology, and the photoresponsive oligonucleic acid molecule modified with azide can be combined by azide-alkyne click chemistry reaction. The photocleavable group and the nucleic acid chain modified by the E3 ligase are covalently linked to UCNP through biotin-streptavidin to form a nanonucleic acid PROTAC system, which enters the cell through endocytosis. Under near-infrared light excitation, a nucleic acid chain that can recruit E3 ubiquitinase at one end and pSMAD3 at one end is released from UCNP. The released nucleic acid chain combines with pSMAD3 transcription factor and E3 ubiquitinase to form a ternary complex. Targeted degradation of pSMAD3 is achieved under the action of proteasome. Compared with previous studies, the present invention newly introduces a near-infrared light-responsive nanodelivery system, which can achieve targeted delivery and near-infrared light-responsive release of nucleic acid PROTACS molecules.

[0086] Experiment 1: Investigate whether thalidomide can be successfully modified on psDTC.

[0087] Polyacrylamide gel electrophoresis experimental process: First, add 2mL 5×TBE buffer solution, 3.93mL deionized water, 70μL 10% APS, 4mL 30% acrylamide-methylene bisacrylamide and 7μL TEMED solution in a 50mL centrifuge tube, vortex and mix to obtain a 12% concentration polyacrylamide gel. Add 1×Tris-Borate-EDTAbuffer (TBE) to the electrophoresis tank, add 10μL of different samples and 2μL of 6×loading buffer to the corresponding channels, and set the electrophoresis parameters to 120V and 60min. Subsequently, place the gel in a newly prepared nucleic acid dye solution (the composition of the nucleic acid dye solution is: a uniform mixture of 2.5mL 5×TBE, 22.5mL deionized water, and 5μL GelRed) for staining for 30min, and use ChampGel TM The gel was imaged using the 7000 system. The distance between the sample and the UV light source was fixed at 1 cm, and 10 μL of 10 μM psDNA10 was irradiated with UV light (10 W) for different times (0 min, 0.5 min, 1 min, 5 min, 10 min, 20 min, 30 min), and the gel electrophoresis results of the reaction samples were observed.

[0088] Figure 6 Schematic diagram (a), gel electrophoresis (b) and mass spectrum (c) of the generation of psDTC by click chemistry of thalidomide and azide-modified psDNA.

[0089] from Figure 6 The gel electrophoresis and mass spectrometry can confirm that thalidomide can be successfully modified on psDTC.

[0090] Figure 710μL 10μM masking aptamer (I), 10μL 10μM psDNA10 (II), 10μL 10μM masking aptamer and 10μL 10μM psDNA10 was annealed and hybridized at 95 degrees for 5 minutes to form APC (Ⅲ), and the product after APC ultraviolet irradiation (Ⅳ); in the gel electrophoresis diagram, lanes Ⅰ and Ⅱ are two high-purity reactant single chains of similar size; lane Ⅲ is the assembly product chain, and a band with a larger molecular weight and darker color and two very light small bands appeared on this lane, confirming the successful assembly of double-stranded APC. The two small bands should be the reaction chains that have not reacted completely, and the positions of the three are one-to-one corresponding; lane Ⅳ is the assembly product chain after ultraviolet irradiation, and there is a dark band with a moderate molecular weight in this lane, which should be the active APC-PASTE successfully released from APC after UV irradiation. Multiple light-colored small bands may be residual reaction chains and broken single chains, etc. By analyzing the gel electrophoresis data, it can be seen that APC was successfully assembled in vitro, and psDTC can be released under ultraviolet conditions to form active PASTE.

[0091] Figure b shows the effect of different UV irradiation times (0, 0.5, 1, 5, 10, 20, 30 min) on the dissociation kinetics of APC: 5 min of UV irradiation is sufficient to induce full cleavage of APC, and as expected, the dissociation rate is positively correlated with the UV irradiation time. In the following experiments, we uniformly used 5 minutes of UV irradiation time to induce APC cleavage.

[0092] Experiment 2: Investigate whether the biotin-modified APC is successfully modified onto the streptavidin-modified upconversion nanoparticles through the biotin-streptavidin interaction.

[0093] The specific experimental process is as follows: the biotinylated masking aptamer chain modified with biotin is annealed and hybridized with the photocleavable psDNA10 with a photocleavable group at 95°C for 5 minutes to form a biotinylated APC. The biotinylated APC is bound to the streptavidin-coated SA-UCNP through the biotin-streptavidin interaction at 37°C overnight to obtain a near-infrared light-controlled nano-nucleic acid PROTAC molecule.

[0094] Dissolve the near-infrared light-controlled nanonucleic acid PROTAC molecules in PBS, take 100 μl and add it to the dynamic light scattering (DLS) detector (Malvern Zetasizer 3000HS) to measure the particle size distribution, take 700 μl and add it to the dynamic light scattering (DLS) detector (Malvern Zetasizer 3000HS) to perform potential measurement; take 10 μl of the sample and drop it on a copper grid, dry it under an incandescent lamp overnight, and then use a JEOL-3010 transmission electron microscope to characterize the morphology of the sample.

[0095] Figure 8 The transmission electron microscopy images, emission spectra, particle size distribution and potential images of near-infrared light-controlled nanonucleic acid PROTAC molecules are shown in Figure 1. In the figure, a is a transmission electron microscopy image of UCNP; the transmission electron microscopy shows that the particle size is uniform and about 50nm, which has little effect on the cell state after entering the cell.

[0096] b is the emission spectra of UCNP and UCNP@APC under near-infrared light irradiation; the near-infrared emission spectrum of UCNP shows an emission peak around 365nm, proving that the nanoparticles can convert 980nm light into 365nm, thereby achieving DNA chain cleavage. The peak of UCNP@APC is basically the same as that of UCNP, indicating that DNA modification has no effect on the emission peak of UCNP.

[0097] c is the particle size distribution diagram of UCNP and UCNP@APC; the particle size distribution diagram shows that after the addition of DNA, the particle size peak shifts to the right, indicating that the particle size becomes larger, which also confirms the successful modification of DNA.

[0098] d is the potential diagram of UCNP and UCNP@APC. The potential diagram shows that after modification with DNA, the potential is more negative than that of UCNP, because DNA is negatively charged. This potential result further confirms the successful modification of DNA.

[0099] Example 2

[0100] Application of a near-infrared light-controlled nanonucleic acid PROTAC molecule in the degradation of tumor transcription factors. Transcription factors such as pSMAD3 inhibit cell migration after degradation. To further evaluate the inhibitory effect of PASTE on the typical Smad pathway, a wound healing assay was used to monitor TGF-β / Smad-dependent cell migration. MCF-7 cells were seeded overnight in 6-well plates to form a confluent monolayer and then scratched with a 10μL sterile pipette tip. The detached cells were washed with PBS and serum-free medium was added to the 6-well plate. After 6μL 100μM PASTE was transfected into MCF-7 cells for 6h, they were stimulated with 25ng / mL TGF-β at 37℃ for 1h, washed 3 times, and cultured in fresh medium for 0h, 6h, and 12h. The speed of wound closure was measured by microscopic bright field imaging (the reduction in scratch surface area was reported as an increase in the percentage of closure).

[0101] Fig. 9 The results of PASTE's inhibition of TGF-β-stimulated MCF-7 cell migration. Compared with the negative control group without TGF-β stimulation, the positive control group with only TGF-β stimulation had 37% of cells growing and migrating at 6 hours, and the cell migration rate reached 48% after 12 hours, which was 20% higher than the negative group in the same period, showing the rapid cell growth and migration mediated by TGF-β / Smad. The experimental group with both TGF-β and PASTE showed that the migration rate was only 24% at 6 hours, 13% lower than the positive group, and inhibited by about 35%; at 12 hours, the migration rate only increased by 3%, which was almost the same as the migration rate of the negative group, 21% lower than the positive group, and inhibited by about 43%.

[0102] Figure b can more clearly show the correlation between the data. At 6 hours, there is a significant difference between the experimental group and the negative group (*p<0.05), and a very significant difference between the experimental group and the positive group (**p<0.01); at 12 hours, there is no difference between the experimental group and the negative group, and there is a significant difference between the experimental group and the positive group (*p<0.05).

[0103] This set of data showed that PASTE significantly inhibited the migration of MCF-7 cells stimulated by TGF-β at 6 and 12 hours, which proved from another level that PASTE can regulate the TGF-β / Smad-dependent signaling pathway by degrading key p-smad2 / 3 proteins and show obvious regulatory effects on the surface.

[0104] Experiment 3: Verify the in vitro NIR response cleavage effect of UCNP@APC.

[0105] Fluorescence spectroscopy was used to verify the in vitro NIR response cleavage effect of UCNP@APC. The specific experimental process was as follows: 10μL 100μM Photocleavable FAM-psDNA and 10μL 100μM Biotinylated BHQ-masking aptamer were annealed and incubated at 95 degrees for 5 minutes to prepare hybrid chain APC, and APC was reacted with 40μg / mL UCNP dissolved in PBS at 37°C overnight. After overnight reaction, centrifugation was performed at 12000rpm for 5 minutes, and the precipitate was resuspended in 500μl PBS. After UCNP@APC was irradiated with an infrared diode laser (MDL-H-980-4W), the supernatant solution irradiated at different times was collected by centrifugation, and the supernatant solution was detected on the fluorescence spectrometer FluoroMax-4.

[0106] The results are as follows Fig.10 As shown in the figure, Photocleavable FAM-psDNA and Biotinylated BHQ-maskingaptamer base complementary chains are modified on UCNP. In theory, under the stimulation of near-infrared light, UCNP will emit UV, thereby activating the cleavage site on APC to make psDNA fall into the solution, and the fluorescence will change from the original quenched state to the activated state. The results show that the fluorescence intensity of FAM gradually increases with the increase of illumination time (0, 5, 10, 20, 30min), and the illumination time of 5min can produce fluorescence changes that are significantly different from the background. It is confirmed that UCNP@APC has good in vitro NIR responsive cleavage performance and can be used for the next step of cell experiments.

[0107] Experiment 4: Use the control variable method to evaluate the degradation effect of p-Smad3.

[0108] Prepare the solution to be added to the cells:

[0109] When the control variable was NIR, the substance added to the cells was 40μg / mL UCNP@APC. 5μL 100μM Biotinylated masking aptamer and 5μL 100uM PhotocleavablepsDNA10 modified with thalidomide were first reacted at 95 degrees for 5 minutes, cooled at 4 degrees, and then reacted with 20μL 2mg / mL UCNP at 37 degrees overnight to prepare UCNP@APC. After centrifugation at 12000rpm for 5 minutes, the cells were resuspended in PBS and all added to MCF-7 cells for incubation for 8 hours. Then they were stimulated with 25ng / mL TGF-β at 37℃ for 1 hour. The cells were washed 3 times, cultured in fresh culture medium for 12 hours, and then collected for Western blot analysis.

[0110] When the control variable was the photocleavable linker, the sample preparation process was the same as that of UCNP@APC, except that 5 μL of 100 μM Photocleavable psDNA10 modified with thalidomide was replaced with 5 μL of 100 μM Photocleavable psDNA10 modified with thalidomide without PC group. After adding it to the cells, incubation was carried out for 8 hours, followed by near-infrared irradiation for 10 minutes and stimulation with 25 ng / mL TGF-β at 37°C for 1 hour. The cells were washed 3 times, cultured in fresh medium for 12 hours, and then collected for Western blot analysis.

[0111] When the control variable is the SBE sequence, the sample preparation process is the same as UCNP@APC, except that 5μL 100μM Photocleavable psDNA10 modified with thalidomide is replaced with 5μL 100μM ControlpsDNA10 (No SBE) modified with thalidomide. After adding it to the cells, incubate for 8 hours, then irradiate with near-infrared for 10 minutes, and stimulate with 25ng / mL TGF-β at 37°C for 1 hour. The cells were washed 3 times, cultured in fresh medium for 12 hours, and then collected for Western blot analysis.

[0112] When the control variable is the SBE sequence, the sample preparation process is the same as UCNP@APC, except that 5μL 100μM Photocleavable psDNA10 modified with thalidomide is replaced with 5μL 100μM pure Photocleavable psDNA10. After adding it to the cells, incubate for 8 hours, then irradiate with near-infrared for 10 minutes, and stimulate with 25ng / mL TGF-β at 37°C for 1 hour. The cells were washed 3 times, cultured in fresh medium for 12 hours, and then collected for Western blot analysis.

[0113] For PASTE treatment, PASTE was first transfected in MCF-7, and 6 μL of 100 μM PASTE and corresponding lipofectamine 3000 were added to each well of a six-well plate. After 6 hours of transfection, the liquid was replaced with 25 ng / mL TGF-β prepared in DMEM (10% FBS + 1% double antibody) and stimulated at 37°C for 1 hour. The cells were washed 3 times, replaced with fresh DMEM (10% FBS + 1% double antibody) and cultured for another 12 hours, and then Western blot analysis was performed. GAPDH was used as an internal control to analyze the expression of Smad3, p-Smad2, p-Smad3 and Smad4, key proteins of the TGF-β / Smad pathway, stimulated by TGF-β.

[0114] The experimental results are as follows Fig.11 As shown in the figure, a is the protein degradation result of psDTC with three different lengths of linkers delivered into the body (psDNA0, psDNA10, psDNA30). Channel 0 is the negative control group, channel 1 is the positive group, and channels 2, 3, and 4 are the psDTC with three different lengths of linkers constructed by us (psDNA0, psDNA10, and psDNA30). Comparing channels 0 and 1, it can be seen that TGF-β treatment successfully activated the TGF-β / Smad pathway and induced Smad2 / 3 phosphorylation. Comparing channels 2, 3, and 4, it can be seen that cells treated with PASTE connected to psDNA10 showed lower p-Smad2 and p-Smad3 levels. After the data was normalized and the correlation analysis was performed, it can be seen that PASTE connected to psDNA10 can effectively reduce the expression levels of p-Smad2 and p-Smad3 in cells, and p-Smad3 showed a more effective reduction ratio than p-Smad2 (45% vs 13%). This may be because the binding affinity of Smad3 to the specific recognition sequence is 3 times higher than that of Smad2, so PASTE binds more to p-Smad3 and shows higher induced degradation than p-Smad2. At the same time, we found that there was no difference in the expression of Smad3 and Smad4 in this group. This may be because the process of p-Smad2 / 3 degradation occurs before the formation of trimers, so Smad4 expression remains unchanged. PASTE linked to psDNA0 and psDNA30 showed low or almost no p-Smad2 / 3 induced degradation, which shows that the appropriate linker length is very important for inducing effective degradation. This experiment successfully demonstrated the feasibility of PASTE-mediated selective degradation of p-Smad2 / 3. In the following experiments, we used PASTE linked to psDNA10.

[0115] Figure b shows the APC treatment, where MCF-7 cells were placed in a 35mm plate, incubated with 1μM APC for 8h, then irradiated with UV light for 5 minutes, and then stimulated with 25ng / mL TGF-β at 37°C for 1h. The cells were washed 3 times, cultured in fresh medium for 12h, and then harvested for Western blot analysis. The WB results are shown in the figure: Compared with the p-smad3 protein content of control group 1, only channel 4, which was transfected with APC and activated by UV light, showed a very significant difference, which decreased by about 59%, and the other two groups without APC or UV light showed no change.

[0116] In the figure, c is UCNP@APC as a PROTAC molecule, and the present invention uses the control variable method to evaluate the degradation effect of p-smad3. The control variable method includes exploring the effects of NIR, photocleavable linkers, SBE sequences, and thalidomide on the degradation results. Consistent with the in vitro results, significant degradation of p-Smad3 can only be detected in cells with intact UCNP@APC structure under near-infrared irradiation, and there are no significant changes in other cell experimental groups lacking any element. Comparing the basic PASTE with a degradation rate of 45% (a in the figure) and the APC with a degradation rate of 59% (b in the figure), the UCNP@APC with the highest degradation efficiency shows a more superior delivery efficiency of 75%, which is significantly different from the control group (**p<0.01).

[0117] Experiment 5: Investigate the temporal correlation between NIR-responsive UCNP@APC and p-Smad3 degradation level.

[0118] The specific experimental process is as follows: First, 40 μg / mL UCNP@APC was prepared. 5 μL 100 μM Biotinylatedmasking aptamer and 5 μL 100 μM Photocleavable psDNA10 modified with thalidomide were first reacted at 95 degrees for 5 minutes, cooled at 4 degrees, and then reacted with 20 μL 2 mg / mL UCNP at 37 degrees overnight to prepare UCNP@APC. After centrifugation at 12000 rpm for 5 minutes, the mixture was resuspended in PBS and added to MCF-7 cells for incubation for 8 hours. After irradiation with near-infrared for 0 minutes, 5 minutes, 10 minutes and 20 minutes, 25 ng / mL TGF-β was used for stimulation at 37°C for 1 hour. The cells were washed 3 times, cultured in fresh culture medium for 12 hours, and then collected for Western blot analysis.

[0119] The results are as follows Fig.12 As shown: With the gradual increase of NIR irradiation time, the protein degradation effect of p-smad3 is gradually enhanced, among which 20 minutes has the best degradation effect. However, considering the phototoxicity and photothermal effects, NIR-10 minutes is selected as the final reaction time.

[0120] Experiment 6: Investigate the concentration correlation between NIR-responsive UCNP@APC and p-Smad3 degradation level.

[0121] The specific experimental process is as follows: 0, 40μg / mL, 20μg / mL, and 10μg / mL UCNP@APC were prepared. 5μL 100μM Biotinylated masking aptamer and 5μL 100μM Photocleavable psDNA10 modified with thalidomide were first reacted at 95 degrees for 5 minutes, cooled at 4 degrees, and then reacted with 20μL 2mg / mL UCNP, 10μL 2mg / mL UCNP, and 5μL 2mg / mL UCNP at 37 degrees overnight to prepare 40μg / mL, 20μg / mL, and 10μg / mL UCNP@APC. After centrifugation at 12000rpm for 5 minutes, the cells were resuspended in PBS and all added to MCF-7 cells for incubation for 8 hours. After irradiation with near-infrared for 0 minutes, 5 minutes, 10 minutes, and 20 minutes, the cells were stimulated with 25ng / mL TGF-β at 37°C for 1 hour. The cells were washed three times and cultured in fresh medium for 12 h before being collected for Western blot analysis.

[0122] The results are as follows Fig.13 As shown: With the gradual increase of concentration, the protein degradation effect of p-smad3 is gradually enhanced, and at 10ug / ml, there is about 25% degradation efficiency, among which 40μg / ml UCNP@APC has the best degradation effect (about 75%). In order to show its best degradation effect, 40μg / ml is selected as the addition concentration of UCNP@APC in the present invention.

[0123] Experiment 7: Investigate the p-Smad3 degradation mechanism mediated by NIR-responsive UCNP@APC.

[0124] The specific experimental process is as follows: cells were treated with the above-mentioned 40 μg / ml UCNP@APC and 5 mM MG132 for 12 hours, and then the cells were collected for Western blot analysis.

[0125] The results are as follows Fig.14 As shown, the proteasome inhibitor MG132 was used to confirm whether the APC-PASTE-mediated p-Smad2 / 3 degradation mechanism depends on the ubiquitin proteasome. The results confirmed that the addition of MG132 indeed inhibited the degradation of p-Smad2 / 3, thus confirming that the protein degradation was indeed caused by the proteasome pathway.

[0126] Experiment 8: Use the CCK8 kit method to evaluate the effects of UCNP@APC and near-infrared irradiation time on cell activity.

[0127] Cell activity experiment process: MCF-7 cells were inoculated in a 96-well plate at a density of 5000 cells / well. After culturing for 24 hours, 40 μg / mL UCNP@APC was carefully added slowly along the inner wall of the 96 wells to prevent MCF-7 cells from detaching from the wall and affecting the experimental results; the 96-well plate was placed in the incubator and taken out after 8 hours. TGF-β was added to stimulate and whether 980nm near-infrared laser (2W) was irradiated for 10 minutes; washed 3 times and cultured in fresh culture medium for 0, 12, 24, and 48 hours. Three parallel experiments were set up for each experiment, and the experiment was repeated 3 times. Finally, the absorbance at 450nm was measured with SpectraMAX M2, and the cell viability was calculated according to the instructions.

[0128] The results are as follows Fig.15 As shown: After 40 μg / mL UCNP@APC was irradiated for 10 min, no obvious cytotoxicity was detected at any time period, proving the good cell affinity of UCNP@APC@IR-10min.

[0129] The above is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as above in the preferred embodiment, it is not used to limit the present invention. Any technician familiar with the art can make many possible changes and modifications to the technical solution of the present invention by using the methods and technical contents disclosed above without departing from the spirit and technical solution of the present invention, or modify it into an equivalent embodiment of equivalent changes. Therefore, any simple modification, equivalent replacement, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention, still fall within the scope of protection of the technical solution of the present invention.

Claims

1. A near-infrared light-controlled nanonucleic acid PROTAC molecule, characterized in that: The invention comprises a biotinylated APC and a SA-UCNP modified with a streptavidin coating, wherein the biotinylated APC is bound to the SA-UCNP modified with a streptavidin coating through a biotin-streptavidin interaction; The biotinylated APC is obtained by coupling psDNA10 with a photocleavable group and an E3 enzyme-linked ligand through a copper-catalyzed azide-alkyne cycloaddition reaction, and then complementary pairing with a biotinylated Masking Aptamer chain to obtain a biotinylated APC; one end of the psDNA10 with a photocleavable group is modified with an azide group; The DNA sequence of the psDNA10 with a photocleavable group is shown in SED ID NO.3; The DNA sequence of the masking aptamer chain modified with biotin is shown in SED ID NO.

4.

2. A method for preparing a near-infrared light-controlled nanonucleic acid PROTAC molecule according to claim 1, characterized in that: The following steps are involved: S1, modifying the alkynyl group on the E3 enzyme-linked ligand to obtain an alkynylated E3 enzyme-linked ligand; S2, subjecting the alkynylated E3 enzyme-linked ligand and the psDNA10 with a photocleavable group to an azide-alkyne cycloaddition reaction under the action of a copper catalyst to obtain the psDNA10 with an E3 enzyme-linked ligand and a photocleavable group; S3, annealing and hybridizing the masking aptamer chain modified with biotin and the psDNA10 with the E3 enzyme-linked ligand and the photocleavable group to form a biotinylated APC; S4. The biotinylated APC is bound to the SA-UCNP modified with the streptavidin coating through the biotin-streptavidin interaction to obtain a near-infrared light-controlled nanonucleic acid PROTAC molecule.

3. The preparation method according to claim 2, characterized in that: The E3 enzyme-linked ligand in the S1 is thalidomide.

4. The preparation method according to claim 2, characterized in that: The preparation method of alkynyl thalidomide comprises the following steps: S1-1, 2-(2-(prop-2-yn-1-yloxy)ethoxy)-1-amine, 2-(2,6-dioxy-3-yl)-4-fluoroisoindole-1,3-dione and N-ethyl-N-isopropyl-2-amine are mixed and stirred in N,N-dimethylformamide to obtain a mixture; S1-2, extracting the mixture with ethyl acetate to obtain an extract; S1-3. The extract is washed with an organic phase and brine successively, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain alkynyl thalidomide.

5. The preparation method according to claim 2, characterized in that: The copper catalyst in S2 includes THPTA, sodium ascorbate and CuSO4.